EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preservation of cell‐free RNA in percutaneous core‐needle biopsy specimens' supernatants from non‐small cell lung cancer improves genomic testing performance

Sheng Xu, Yi-Dan Ma, Zhi-Xin Bie, Jing-Yu Huang, Yuan-Ming Li, Zheng Wang, Xiao-Guang Li

The Journal of Pathology: Clinical Research · 2026-03 · 12 (2)

DOI: 10.1002/2056-4538.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 26.02.2026. Verfasst von Sheng Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese A…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids, Genetic Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical and Translational Medical Research Fund of the Chinese Academy of Medical Sciences, Capital's Funds for Health Improvement and Research, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This prospective single‐center study aimed to investigate whether preserving cell‐free ribonucleic acid (cfRNA) in specimens' supernatants (SS) obtained from percutaneous core‐needle biopsy (CNB) of non‐small cell lung cancer (NSCLC) can improve the performance of genomic testing. Forty‐three NSCLC patients who underwent image‐guided CNB were enrolled. The SS from each CNB specimen was divided into two parts: one was mixed 1:1 with a cfRNA‐protective solution, and the other was left unhandled. For quantitative analysis, 30 patients (regardless of mutation status) were evaluated by comparing cfRNA yield between cfRNA‐protected and ‐unprotected SS. For qualitative analysis, 15 patients with fusion gene alterations were assessed by comparing genotyping results from cfRNA‐protected SS to those from paired CNB specimens. Pneumothorax was the most frequent adverse event in CNB procedures, occurring in 20.9% of cases (9/43). No one experienced severe adverse events. In the quantitative analysis, 90.0% (27/30) of cfRNA‐protected SS yielded adequate cfRNA, significantly higher than 53.3% (16/30) in cfRNA‐unprotected SS ( p < 0.01). In the qualitative analysis, despite ineffective cfRNA preservation in three cases, DNA‐level mutations were still detected in both the CNB specimens and cfRNA‐protected SS. The overall concordance of genotyping results between cfRNA‐protected SS and paired CNB specimens was 100%, correctly identifying all ALK fusions, ROS1 rearrangements, and MET‐14 skipping alterations. These findings highlight that preserving cfRNA in CNB‐SS from NSCLC can improve the performance of genomic testing, particularly for RNA‐based assays, without compromising the accuracy of DNA‐based assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell-Free Nucleic AcidsGenetic TestingBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedProspective StudiesBiopsy, Large-Core NeedleMutationAdult

Stichwörter der Autor:innen

RNAcore‐needle biopsygenomic testinglung cancersupernatants

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Pathology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

Förderung

  • Clinical and Translational Medical Research Fund of the Chinese Academy of Medical Sciences
  • Capital's Funds for Health Improvement and Research
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Xu, S., Ma, Y. D., Bie, Z. X., Huang, J. Y., Li, Y. M., Wang, Z., & Li, X. G. (2026). Preservation of cell‐free RNA in percutaneous core‐needle biopsy specimens' supernatants from non‐small cell lung cancer improves genomic testing performance. The Journal of Pathology: Clinical Research, 12(2). https://doi.org/10.1002/2056-4538.70081

Vancouver

Xu S, Ma YD, Bie ZX, Huang JY, Li YM, Wang Z, et al. Preservation of cell‐free RNA in percutaneous core‐needle biopsy specimens' supernatants from non‐small cell lung cancer improves genomic testing performance. The Journal of Pathology: Clinical Research. 2026;12(2). doi:10.1002/2056-4538.70081

BibTeX
@article{Xu2026,
  author = {Xu, Sheng and Ma, Yi-Dan and Bie, Zhi-Xin and Huang, Jing-Yu and Li, Yuan-Ming and Wang, Zheng and Li, Xiao-Guang},
  title = {Preservation of cell‐free RNA in percutaneous core‐needle biopsy specimens' supernatants from non‐small cell lung cancer improves genomic testing performance},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1002/2056-4538.70081}
}
Kostenlos starten →